Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

CYP2D6 has received intense attention since the beginning of the pharmacogenetic era in
the 1970s. This is because of its involvement in the metabolism of more than 25% of the …

The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and
CYP2C19 metabolic phenotypes ('predicted'from genotypes and 'measured'with a probe …

The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …

Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …

What is known and objective Genetic polymorphism is one of the most important factors
responsible for interindividual and interethnic variability in drug response. Studies in major …

Phase I and II drug metabolizing enzymes (DME) and drug transporters are involved in the
absorption, distribution, metabolism as well as elimination of many therapeutic agents …

Abstract Cytochrome P450 (CYP) 2D6 is present in less than about 2% of all CYP enzymes
in the liver, but it is involved in the metabolism of about 25% of currently used drugs …

BACKGROUND & AIMS: Previous observational studies reported that concomitant use of
clopidogrel and proton pump inhibitors (PPIs) in patients with prior acute coronary syndrome …